Cargando…

The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience

This study revisited the Dohner prognostic hierarchy in a cohort of 1585 well‐documented patients with chronic lymphocytic leukaemia. The duration of both time to first treatment (TTFT) and overall survival (OS) were significantly longer than observed previously, and this is at least partly due to i...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Dyke, Daniel L., Werner, Lillian, Rassenti, Laura Z., Neuberg, Donna, Ghia, Emanuella, Heerema, Nyla A., Dal Cin, Paola, Dell Aquila, Marie, Sreekantaiah, Chandrika, Greaves, Andrew W., Kipps, Thomas J., Kay, Neil E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4963001/
https://www.ncbi.nlm.nih.gov/pubmed/26848054
http://dx.doi.org/10.1111/bjh.13933
_version_ 1782444896357974016
author Van Dyke, Daniel L.
Werner, Lillian
Rassenti, Laura Z.
Neuberg, Donna
Ghia, Emanuella
Heerema, Nyla A.
Dal Cin, Paola
Dell Aquila, Marie
Sreekantaiah, Chandrika
Greaves, Andrew W.
Kipps, Thomas J.
Kay, Neil E.
author_facet Van Dyke, Daniel L.
Werner, Lillian
Rassenti, Laura Z.
Neuberg, Donna
Ghia, Emanuella
Heerema, Nyla A.
Dal Cin, Paola
Dell Aquila, Marie
Sreekantaiah, Chandrika
Greaves, Andrew W.
Kipps, Thomas J.
Kay, Neil E.
author_sort Van Dyke, Daniel L.
collection PubMed
description This study revisited the Dohner prognostic hierarchy in a cohort of 1585 well‐documented patients with chronic lymphocytic leukaemia. The duration of both time to first treatment (TTFT) and overall survival (OS) were significantly longer than observed previously, and this is at least partly due to improved therapeutic options. Deletion 13q remains the most favourable prognostic group with median TTFT and OS from fluorescence in situ hybridization (FISH) testing of 72 months and >12 years, respectively. Deletion 11q had the poorest median TTFT (22 months) and 17p deletion the poorest median OS (5 years). The percentages of abnormal nuclei were significantly associated with differential TTFT for the trisomy 12, 13q and 17p deletion cohorts but not for the 11q deletion cohort. From the date of the first FISH study, patients with >85% 13q deletion nuclei had a notably shorter TTFT (24 months). Patients with ≤20% 17p deletion nuclei had longer median TTFT and OS from the date of the first FISH study (44 months and 11 years), and were more likely to be IGHV mutated.
format Online
Article
Text
id pubmed-4963001
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-49630012016-07-27 The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience Van Dyke, Daniel L. Werner, Lillian Rassenti, Laura Z. Neuberg, Donna Ghia, Emanuella Heerema, Nyla A. Dal Cin, Paola Dell Aquila, Marie Sreekantaiah, Chandrika Greaves, Andrew W. Kipps, Thomas J. Kay, Neil E. Br J Haematol Haematological Malignancy This study revisited the Dohner prognostic hierarchy in a cohort of 1585 well‐documented patients with chronic lymphocytic leukaemia. The duration of both time to first treatment (TTFT) and overall survival (OS) were significantly longer than observed previously, and this is at least partly due to improved therapeutic options. Deletion 13q remains the most favourable prognostic group with median TTFT and OS from fluorescence in situ hybridization (FISH) testing of 72 months and >12 years, respectively. Deletion 11q had the poorest median TTFT (22 months) and 17p deletion the poorest median OS (5 years). The percentages of abnormal nuclei were significantly associated with differential TTFT for the trisomy 12, 13q and 17p deletion cohorts but not for the 11q deletion cohort. From the date of the first FISH study, patients with >85% 13q deletion nuclei had a notably shorter TTFT (24 months). Patients with ≤20% 17p deletion nuclei had longer median TTFT and OS from the date of the first FISH study (44 months and 11 years), and were more likely to be IGHV mutated. John Wiley and Sons Inc. 2016-02-05 2016-04 /pmc/articles/PMC4963001/ /pubmed/26848054 http://dx.doi.org/10.1111/bjh.13933 Text en © 2016 The Authors. British Journal of Haematology published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Haematological Malignancy
Van Dyke, Daniel L.
Werner, Lillian
Rassenti, Laura Z.
Neuberg, Donna
Ghia, Emanuella
Heerema, Nyla A.
Dal Cin, Paola
Dell Aquila, Marie
Sreekantaiah, Chandrika
Greaves, Andrew W.
Kipps, Thomas J.
Kay, Neil E.
The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience
title The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience
title_full The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience
title_fullStr The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience
title_full_unstemmed The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience
title_short The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience
title_sort dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (cll): the cll research consortium experience
topic Haematological Malignancy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4963001/
https://www.ncbi.nlm.nih.gov/pubmed/26848054
http://dx.doi.org/10.1111/bjh.13933
work_keys_str_mv AT vandykedaniell thedohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience
AT wernerlillian thedohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience
AT rassentilauraz thedohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience
AT neubergdonna thedohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience
AT ghiaemanuella thedohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience
AT heeremanylaa thedohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience
AT dalcinpaola thedohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience
AT dellaquilamarie thedohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience
AT sreekantaiahchandrika thedohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience
AT greavesandreww thedohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience
AT kippsthomasj thedohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience
AT kayneile thedohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience
AT vandykedaniell dohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience
AT wernerlillian dohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience
AT rassentilauraz dohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience
AT neubergdonna dohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience
AT ghiaemanuella dohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience
AT heeremanylaa dohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience
AT dalcinpaola dohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience
AT dellaquilamarie dohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience
AT sreekantaiahchandrika dohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience
AT greavesandreww dohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience
AT kippsthomasj dohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience
AT kayneile dohnerfluorescenceinsituhybridizationprognosticclassificationofchroniclymphocyticleukaemiacllthecllresearchconsortiumexperience